Lheureux Stephanie, Karakasis Katherine, Kohn Elise C, Oza Amit M
Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10.
The diagnosis, investigation, and management of ovarian cancer are in a state of flux-balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence-informed manner to gradually improve outcome. Has this improved understanding of the biology and associated calls to action led to appropriate changes in therapy? In this review, the authors discuss incorporating emerging data on biology, combinations, dose, and scheduling of new and existing agents with patient preferences in the management of women with ovarian cancer.
卵巢癌的诊断、检查及治疗正处于不断变化之中——这是在我们对其生物学特性的认识取得飞速进展的同时，历经30年临床试验所达成的一种平衡。始于经验性选择的临床试验已以循证方式不断演进，逐步改善了治疗结果。对生物学特性的这种深入理解以及相关行动呼吁是否带来了治疗方面的适当改变？在这篇综述中，作者们探讨了如何在卵巢癌女性患者的治疗中，将有关生物学特性、联合用药、新药及现有药物的剂量和给药方案的新数据与患者偏好相结合。
